Financial Performance - The company achieved revenue of RMB 458.4 million for the six months ended June 30, 2024, representing a 13.6% increase compared to RMB 403.6 million in the same period of 2023[3]. - Gross profit for the reporting period was RMB 363.1 million, up 12.9% from RMB 321.8 million in the previous year[3]. - Net profit attributable to the parent company increased by 11.9% to RMB 285.8 million from RMB 255.5 million in 2023[3]. - Adjusted net profit under non-HKFRS increased by 15.9% to RMB 274.9 million from RMB 237.2 million in the prior year[3]. - Basic and diluted earnings per share were RMB 24.39, reflecting an increase of 11.7% and 12.2% respectively compared to RMB 21.83 and RMB 21.73 in 2023[3]. - The company reported a total comprehensive income of RMB 277.5 million for the period, compared to RMB 226.2 million in the same period last year[8]. - The increase in sales was primarily attributed to the rise in sales of one-time products[1]. - The company reported a significant increase in other income and gains, totaling RMB 115.4 million compared to RMB 93.8 million in the previous year[6]. - Operating cash flow before tax profit for the six months ended June 30, 2024, was RMB 327,733 thousand, an increase of 20.8% from RMB 271,282 thousand in 2023[11]. - Net cash flow from operating activities for the six months ended June 30, 2024, was RMB 221,722 thousand, up 30.7% from RMB 169,550 thousand in 2023[12]. Assets and Liabilities - Total assets less current liabilities amounted to RMB 2,381.8 million as of June 30, 2024, down from RMB 4,072.9 million at the end of 2023[10]. - The company reported a total of RMB 30,149,000 in trade payables as of June 30, 2024, compared to RMB 34,146,000 as of December 31, 2023, indicating a decrease of about 11.7%[34]. - The company has a total of RMB 117,521,000 in prepayments, other receivables, and other assets as of June 30, 2024, significantly up from RMB 9,711,000 as of December 31, 2023[30]. - The company’s total liabilities, including trade payables and other payables, amounted to RMB 245,223,000 as of June 30, 2024, compared to RMB 82,084,000 as of December 31, 2023[35]. - The net current asset value decreased to RMB 1,571.4 million as of June 30, 2024, down RMB 1,618.5 million from RMB 3,189.9 million as of December 31, 2023, primarily due to the declaration and distribution of special dividends totaling RMB 1,663.9 million[69]. Cash Flow and Investments - Cash and cash equivalents at the end of June 30, 2024, totaled RMB 2,915,728 thousand, significantly up from RMB 663,744 thousand in 2023[13]. - Net cash flow from investing activities for the six months ended June 30, 2024, was RMB 1,213,364 thousand, compared to a cash outflow of RMB 1,249,899 thousand in 2023[12]. - The company’s cash flow from interest received was RMB 36,447 thousand for the six months ended June 30, 2024, compared to RMB 9,268 thousand in 2023[12]. - The company has confirmed compliance with the Corporate Governance Code during the reporting period[79]. - The company plans to utilize the net proceeds from its global offering for strategic investments and capital asset acquisitions for expansion[73]. Revenue Breakdown - Sales of medical devices in mainland China reached RMB 418,213,000, up from RMB 364,464,000, representing a growth of 14.8% year-over-year[19]. - Domestic revenue growth was driven by increased sales of core disposable products, including disposable puncture devices and hemostatic clips, as well as strong year-on-year growth in new products like ultrasonic cutting hemostatic devices[38]. - Export sales reached RMB 40.2 million for the six months ended June 30, 2024, reflecting a 2.7% increase year-on-year, primarily due to sales growth in the European market[39]. - Sales of disposable products reached RMB 409.1 million, accounting for approximately 89.3% of total revenue, with a growth of 19.6% from RMB 342.0 million in 2023[47]. - The revenue from disposable electrocautery forceps was RMB 67.0 million, representing a growth of 30.2% compared to RMB 51.5 million in 2023, and accounted for about 14.6% of total revenue[49]. Research and Development - The company registered 12 new products in China during the reporting period, bringing the total to 104 registered products as of June 30, 2024[41]. - The company has completed clinical trials for its four-arm surgical robot system and expects regulatory approval by the end of 2024[42]. - A new research and development building was put into use in June 2024, enhancing the company's innovation and product development capabilities[42]. - The company has obtained 20 new patents during the reporting period, with its subsidiary, Weijing Medical, securing an additional 50 patents[41]. - Research and development expenses decreased by 27.8% to RMB 43.4 million, down from RMB 60.1 million in the previous year, due to reduced R&D spending at Weijing Medical[60]. Shareholder Returns - The company did not recommend any interim dividend for the six months ended June 30, 2024[4]. - The company approved a final dividend of RMB 0.41 per ordinary share, totaling approximately RMB 1,700,749,000, to be paid on July 18, 2024[25]. - The company repurchased a total of 5,509,500 shares at a total cost of approximately HKD 33.8 million for the six months ended June 30, 2024, compared to HKD 15.7 million for the same period in 2023[82]. - A total of 1,490,500 shares were canceled during the six months ended June 30, 2024, with an additional 4,619,000 shares canceled after the reporting period[82]. Employee and Compensation - As of June 30, 2024, the group had 964 employees, a decrease from 982 employees as of June 30, 2023[74]. - Total employee compensation expenses for the six months ended June 30, 2024, amounted to RMB 736 million, compared to RMB 679 million for the same period in 2023[74].
康基医疗(09997) - 2024 - 中期业绩